France's Adocia Completes 2012's First Euro Biotech IPO

French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes

In the first biopharma IPO in Europe this year, the French drug delivery company Adocia SAS has raised €25 million ($32.7 million) on NYSE Euronext Paris, in an offering that was oversubscribed.

The listing comes over nine months since Europe’s last biopharma IPO, that of dermatology-focused Moberg Pharma AB in May...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from France

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

French Bill Could Improve Clinical Research, But Further Action Is Required

 

France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.

France’s New Carbon Footprint Measuring Method Could Guide Purchasing Decisions

 

A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.

France Finally Passes Price Cutting Finance Bill – With Some Amendments

 

Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.

More from Europe

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.